Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.52 |
| ▸ | PPARD | Q03181 | 7/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanoic Acid SCHEMBL28646037 | 1.00 | GPR84 (0.52) | GPR84PPARGPPARDPPARAHDAC11 | |
| Undecanoate SCHEMBL28132949 | 1.00 | GPR84 (0.52) | GPR84PPARGPPARDPPARAHDAC11 | |
| Hexanoate SCHEMBL11045296 | 0.98 | AKR1B1 (0.50) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL30231127 | 0.98 | GPR84 (0.53) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL9387065 | 0.94 | GPR84 (0.55) | GPR84PPARGPPARDPPARAHDAC11 | |
| Caprolactam SCHEMBL8162069 | 0.94 | FKBP5 (0.52) | GPR84PPARGPPARDPPARAHDAC11 | |
| Tridecanoate SCHEMBL10007182 | 0.94 | GPR84 (0.55) | GPR84PPARGPPARDPPARAHDAC11 | |
| Octanoic Acid SCHEMBL8989223 | 0.93 | GPR84 (0.45) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL1982539 | 0.92 | GPR84 (0.53) | GPR84PPARGPPARDPPARAHDAC11 | |
| Hexanoate SCHEMBL7413873 | 0.92 | AKR1B1 (0.53) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190952-A1 | IL-18 Binding Protein (IL-18BP) and Antibodies for Treating Inflammatory Diseases | AB2 BIO SA (CH) | 2024-06-13 | — | — | US | disclosed |
| US-11926663-B2 | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases | AB2 BIO SA (CH) | 2024-03-12 | — | — | US | disclosed |
| US-11897942-B2 | Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies | Temple University—Of the Commonwealth System of Higher Education (US) | 2024-02-13 | — | — | US | disclosed |
| US-11820817-B2 | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases | AB2 BIO SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20230250164-A1 | IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases | AB2 BIO SA (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230173021-A1 | IL-18 Binding Protein (IL-18BP) In Respiratory Diseases | AB2 BIO SA (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4185313-A1 | AVOIDING OR MINIMIZING SIDE-EFFECTS RELATED TO CAR-T-CELL THERAPY | AB2 Bio SA (CH) | 2023-05-31 | — | — | EP | disclosed |
| EP-4146174-A1 | IL-18 BINDING PROTEIN (IL-18BP) IN RESPIRATORY DISEASES | AB2 Bio SA (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-20220401476-A1 | CAR-T-CELL THERAPY | AB2 BIO SA (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11530263-B2 | IL-18 binding protein (IL-18BP) in inflammatory diseases | AB2 BIO SA (CH) | 2022-12-20 | — | — | US | disclosed |
| US-20110195114-A1 | TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS | ANTARES PHARMA, IPL, AG | 2011-08-11 | — | — | US | disclosed |
| US-20100255130-A1 | ALOE PREPARATION FOR SKIN ENHANCEMENT | ALOEBIOTICS RESEARCH LABS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7470433-B2 | Formulations for transdermal or transmucosal application | ANTARES PHARMA IPL AG (CH) | 2008-12-30 | — | — | US | disclosed |
| US-20080025920-A1 | METHODS OF TREATING HOT FLASHES WITH FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION | ANTARES PHARMA IPL AG (CH) | 2008-01-31 | — | — | US | disclosed |
| US-20070166361-A1 | FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION | ANTARES PHARMA IPL AG | 2007-07-19 | — | — | US | disclosed |
| US-7198801-B2 | Formulations for transdermal or transmucosal application | ANTARES PHARMA IPL AG (CH) | 2007-04-03 | — | — | US | disclosed |
| US-20070053968-A1 | Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054964-A1 | Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its salts | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20040219197-A1 | Formulations for transdermal or transmucosal application | ANTARES PHARMA, IPL, AG (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040198706-A1 | Methods and formulations for transdermal or transmucosal application of active agents | ANTARES PHARMA, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198706-A1 | Methods and formulations for transdermal or transmucosal application of active agents | SHBG, CYP17A1, NR5A1 | GPR84 967/4885PPARG 1853/4885PPARD 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.